CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gualandris, A.
Right arrow Articles by Presta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gualandris, A.
Right arrow Articles by Presta, M.

Cell Growth & Differentiation, Vol 7, Issue 2 147-160, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases

A Gualandris, M Rusnati, M Belleri, EE Nelli, M Bastaki, MP Molinari-Tosatti, F Bonardi, S Parolini, A Albini, L Morbidelli, M Ziche, A Corallini, L Possati, A Vacca, D Ribatti and M Presta
Department of Biomedical Sciences and Biotechnology, University of Brescia, Italy.

Basic fibroblast growth factor (bFGF) is expressed in vascular endothelium during tumor neovascularization and angioproliferative diseases. The ultimate significance of this observation is poorly understood. We have investigated the biological consequences of endothelial cell activation by endogenous bFGF in a mouse aortic endothelial cell line stably transfected with a retroviral expression vector harboring a human bFGF cDNA. Selected clones expressing M(r) 24,000, M(r) 22,000, and/or M(r) 18,000 bFGF isoforms were characterized by a transformed morphology and an increased saturation density. bFGF transfectants showed invasive behavior and sprouting activity in three-dimensional fibrin gels and formed a complex network of branching cord-like structures connecting foci of infiltrating cells when seeded on laminin-rich basement membrane matrix (Matrigel). The invasive and morphogenetic behavior was prevented by anti-bFGF antibody, revealing the autocrine modality of the process. The biological consequences of this autocrine activation were investigated in vivo. bFGF-transfected cells gave rise to highly vascularized lesions resembling Kaposi's sarcoma when injected in nude mice and induced angiogenesis in avascular rabbit cornea. When injected into the allantoic sac of the chick embryo, they caused an increase in vascular density and formation of hemangiomas in the chorioallantoic membrane. In conclusion, bFGF-overexpressing endothelial cells acquired an angiogenic phenotype and recruit quiescent endothelium originating angioproliferative lesions in vivo. These findings demonstrate that bFGF overexpression exerts an autocrine role for endothelial cells and support the notion that tumor neovascularization and angioproliferative diseases can be triggered by stimuli that induce vascular endothelium to produce its own autocrine factor(s).


This article has been cited by other articles:


Home page
J EndocrinolHome page
A. Diane, N. Nikolic, A. P. Rudecki, S. M. King, D. J. Bowie, and S. L. Gray
PACAP is essential for the adaptive thermogenic response of brown adipose tissue to cold exposure
J. Endocrinol., September 1, 2014; 222(3): 327 - 339.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. Rousselet, S. Traver, Y. Monnet, A. Perrin, N. Mandjee, A. Hild, E. C. Hirsch, T. S. Zheng, and S. Hunot
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Induces Astrocyte Proliferation through the Activation of Transforming-Growth Factor-{alpha}/Epidermal Growth Factor Receptor Signaling Pathway
Mol. Pharmacol., November 1, 2012; 82(5): 948 - 957.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Liekens, A. Bronckaers, M. Belleri, A. Bugatti, R. Sienaert, D. Ribatti, B. Nico, A. Gigante, E. Casanova, G. Opdenakker, et al.
The Thymidine Phosphorylase Inhibitor 5'-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist
Mol. Cancer Ther., April 1, 2012; 11(4): 817 - 829.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. Finetti, S. Donnini, A. Giachetti, L. Morbidelli, and M. Ziche
Prostaglandin E2 Primes the Angiogenic Switch via a Synergic Interaction With the Fibroblast Growth Factor-2 Pathway
Circ. Res., September 25, 2009; 105(7): 657 - 666.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Belleri, D. Ribatti, M. Savio, L. A. Stivala, L. Forti, E. Tanghetti, P. Alessi, D. Coltrini, A. Bugatti, S. Mitola, et al.
{alpha}v{beta}3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers
Mol. Cancer Ther., December 1, 2008; 7(12): 3761 - 3770.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Leali, E. Moroni, F. Bussolino, and M. Presta
Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement
J. Biol. Chem., July 6, 2007; 282(27): 19676 - 19684.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Liekens, S. Gijsbers, E. Vanstreels, D. Daelemans, E. De Clercq, and S. Hatse
The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells
Mol. Pharmacol., March 1, 2007; 71(3): 695 - 703.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Stabile, S. Mitola, E. Moroni, M. Belleri, S. Nicoli, D. Coltrini, F. Peri, A. Pessi, L. Orsatti, F. Talamo, et al.
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
Blood, March 1, 2007; 109(5): 1834 - 1840.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli
Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al.
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma
J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. He, T. E. Peterson, and Z. S. Katusic
Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8
Am J Physiol Heart Circ Physiol, July 12, 2005; 289(2): H968 - H972.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta
Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4'-Trimethoxystilbene
Mol. Pharmacol., May 1, 2005; 67(5): 1451 - 1459.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Presta, P. Oreste, G. Zoppetti, M. Belleri, E. Tanghetti, D. Leali, C. Urbinati, A. Bugatti, R. Ronca, S. Nicoli, et al.
Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists
Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 71 - 76.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Rusnati, M. Camozzi, E. Moroni, B. Bottazzi, G. Peri, S. Indraccolo, A. Amadori, A. Mantovani, and M. Presta
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis
Blood, July 1, 2004; 104(1): 92 - 99.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Morbidelli, S. Donnini, F. Chillemi, A. Giachetti, and M. Ziche
Angiosuppressive and Angiostimulatory Effects Exerted by Synthetic Partial Sequences of Endostatin
Clin. Cancer Res., November 1, 2003; 9(14): 5358 - 5369.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Leali, P. Dell'Era, H. Stabile, B. Sennino, A. F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, and M. Presta
Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis
J. Immunol., July 15, 2003; 171(2): 1085 - 1093.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Leali, M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta
Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives
J. Biol. Chem., October 12, 2001; 276(41): 37900 - 37908.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Liekens, J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta
Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir
Cancer Res., July 1, 2001; 61(13): 5057 - 5064.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. V. Bhagwat, J. Lahdenranta, R. Giordano, W. Arap, R. Pasqualini, and L. H. Shapiro
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
Blood, February 1, 2001; 97(3): 652 - 659.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta
Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors
Cancer Res., January 1, 2001; 61(1): 309 - 317.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Parenti, L. Brogelli, S. Donnini, M. Ziche, and F. Ledda
ANG II potentiates mitogenic effect of norepinephrine in vascular muscle cells: role of FGF-2
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H99 - H107.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. W. Baish and R. K. Jain
Fractals and Cancer
Cancer Res., July 1, 2000; 60(14): 3683 - 3688.
[Abstract] [Full Text]


Home page
JCBHome page
J. Y. Pan, W. E. Fieles, A. M. White, M. M. Egerton, and D. S. Silberstein
Ges, a Human Gtpase of the Rad/Gem/Kir Family, Promotes Endothelial Cell Sprouting and Cytoskeleton Reorganization
J. Cell Biol., May 29, 2000; 149(5): 1107 - 1116.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
R. Mohan, J. Sivak, P. Ashton, L. A. Russo, B. Q. Pham, N. Kasahara, M. B. Raizman, and M. E. Fini
Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B
J. Biol. Chem., April 7, 2000; 275(14): 10405 - 10412.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
R. Giuliani, M. Bastaki, D. Coltrini, and M. Presta
Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2
J. Cell Sci., August 1, 1999; 112(15): 2597 - 2606.
[Abstract] [PDF]


Home page
Cancer Res.Home page
S. Liekens, E. Verbeken, M. Vandeputte, E. De Clercq, and J. Neyts
A Novel Animal Model for Hemangiomas: Inhibition of Hemangioma Development by the Angiogenesis Inhibitor TNP-470
Cancer Res., May 1, 1999; 59(10): 2376 - 2383.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Presta, M. Rusnati, M. Belleri, L. Morbidelli, M. Ziche, and D. Ribatti
Purine Analogue 6-Methylmercaptopurine Riboside Inhibits Early and Late Phases of the Angiogenesis Process
Cancer Res., May 1, 1999; 59(10): 2417 - 2424.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Vacca, D. Ribatti, M. Presta, M. Minischetti, M. Iurlaro, R. Ria, A. Albini, F. Bussolino, and F. Dammacco
Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma
Blood, May 1, 1999; 93(9): 3064 - 3073.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Ziche, A. Parenti, F. Ledda, P. Dell'Era, H. J. Granger, C. A. Maggi, and M. Presta
Nitric Oxide Promotes Proliferation and Plasminogen Activator Production by Coronary Venular Endothelium Through Endogenous bFGF
Circ. Res., June 19, 1997; 80(6): 845 - 852.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Bastaki, E. E. Nelli, P. Dell'Era, M. Rusnati, M. P. Molinari-Tosatti, S. Parolini, R. Auerbach, L. P. Ruco, L. Possati, and M. Presta
Basic Fibroblast Growth Factor Induced Angiogenic Phenotype in Mouse Endothelium : A Study of Aortic and Microvascular Endothelial Cell Lines
Arterioscler Thromb Vasc Biol, March 1, 1997; 17(3): 454 - 464.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
D. Leali, M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta
Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives
J. Biol. Chem., July 24, 2001; (2001) 105163200.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.